

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listing of claims in the application:

1. (Currently Amended) A transgenic mouse non-human mammal or a portion thereof, wherein [[an]] a human α-synuclein gene with a C-terminal deletion linked to a tyrosine hydroxylase promoter is introduced and the gene is expressed in the neurons, and the number of dopamine-producing neurons in the substantia nigra is significantly decreased as compared with that of a wild-type animal.
2. (Cancelled)
3. (Currently Amended) The transgenic mouse non-human mammal or a portion thereof according to claim 1, wherein the α-synuclein gene is a variant of a wild-type human α-synuclein gene in a manner that substitutes a has substitution of a Thr residue for an Ala residue at amino acid residue 53 in an amino acid sequence encoded by the wild-type human α-synuclein gene.
- 4.-7. (Cancelled)
8. (Currently Amended) The transgenic mouse non-human mammal or a portion thereof according to claim 1, wherein the transgenic mouse has at least 85% decrease in[[an]] intracerebral dopamine level at an early age of at least 5 days is decreased to 85% or less as compared with that of to a wild-type mouse animal.
9. (Currently Amended) The transgenic mouse non-human mammal or a portion thereof according to claim 1, wherein the transgenic mouse has at least a tyrosine hydroxylase expression level is decreased to 80% decrease in intracerebral tyrosine hydroxylase level or less as compared with that of to a wild-type mouse animal.
10. (Currently Amended) The transgenic mouse non-human mammal or a portion thereof

according to claim 1, wherein the transgenic mouse has at least a spontaneous locomotor activity is decreased to 60% decrease in spontaneous locomotor activity or less as compared with that of to a wild-type mouse animal.

11.-13. (Cancelled)

14. (Withdrawn – Currently Amended) A substance obtained by [[the]] performing a method for screening a substance having dopamine-like action, wherein the transgenic mouse according to claim 1 is used screening method according to claim 12.

15. (Withdrawn – Currently Amended) A therapeutic agent or preventive agent for Parkinson's disease which comprises a substance obtained by the screening method according to claim 12 claim 14, as an active ingredient.

16. (New) The transgenic mouse according to claim 1, wherein the α -synuclein gene is expressed in the neurons, and the transgenic mouse has at least 50% decrease in the number of dopamine-producing neurons in the substantia nigra as compared to a wild type mouse.